Loading clinical trials...

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT) | Clinical Trials | Clareo Health

COMPLETEDPHASE3

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis

NCT04417894•Regeneron Pharmaceuticals

View on ClinicalTrials.gov

Summary

The primary objective of the study is to assess the efficacy of dupilumab on skin lesions in patients with atopic hand and foot dermatitis. The secondary objectives of the study are: * To assess the efficacy of dupilumab on various other domains (pruritus, pain, sleep loss, health related QoL, work life impairment) in patients with atopic hand and foot dermatitis * To evaluate the safety and tolerability of dupilumab administered to patients with atopic hand and foot dermatitis * To evaluate systemic exposure and immunogenicity of dupilumab in patients with atopic hand and foot dermatitis

Eligibility

Age

12 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with involvement of at least 2 anatomical areas at screening and baseline
•Patients need to have an IGA hand and foot score of 3 or 4 (moderate-to-severe disease) at screening and baseline
•Patients with documented recent history (within 6 months before the screening visit) of inadequate response of atopic hand and foot dermatitis to topical medication(s)
•Patients meet the diagnosis criteria for atopic dermatitis (AD)
•Provide informed consent/assent signed by study patient or legally acceptable representative
•Patients need to have been compliant with the skin protection measures through the entire duration of the screening period

Exclusion Criteria

•Treatment with dupilumab in the past
•Patients with a positive patch test reaction that are deemed to be clinically relevant as the current cause of the hand and foot dermatitis
•Patients with documented exposure to irritants believed to be a predominant cause of the current hand and foot dermatitis
•Treatment with systemic corticosteroids or non-steroidal immunosuppressive drugs within 4 weeks prior to baseline
•Known history of HIV/HBV/HCV infection
•Pregnant or breastfeeding women or planning to become pregnant or breastfeed during the patient's participation in this study
•Women of childbearing potential (WOCBP) who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment and during the study

Locations (48)

Regeneron Study Site

Birmingham, Alabama, United States

Regeneron Study Site

Redwood City, California, United States

Regeneron Study Site

Washington D.C., District of Columbia, United States

Regeneron Study Site

Macon, Georgia, United States

Regeneron Study Site

Sandy Springs, Georgia, United States

Regeneron Study Site

Columbus, Indiana, United States

Regeneron Study Site

Rockville, Maryland, United States

Regeneron Study Site

Saint Joseph, Missouri, United States

Regeneron Study Site

St Louis, Missouri, United States

Regeneron Study Site

Kew Gardens, New York, United States

Key Dates

Start Date

April 14, 2021

Primary Completion Date

August 31, 2022

Completion Date

November 23, 2022

Last Updated

December 22, 2023

Enrollment

133

ACTUAL participants

Conditions

Moderate to Severe Atopic Hand and Foot Dermatitis

Interventions

dupilumab

DRUG

Placebo

DRUG